Skip to Main Content

When the Trump administration released its blueprint for coping with high drug costs last month, one particular idea was widely derided — requiring drug makers to include list prices in consumer advertising.

That’s because drug pricing is highly confusing and few people actually pay list prices. Nonetheless, the White House seems to believe that such transparency could force companies to compete on price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • C’mon Globe – a story headline is embedded in the business section and readers have to “pay” (subscribe) to STAT+ to get the content?? The word “deceptive” comes to mind.

Comments are closed.